Q-omics provides the consensus-scored ANKFY1 profile across patient tissues and cancer cell-line models. ANKFY1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, ANKFY1 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, ANKFY1 protein abundance shows 22,601 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SCLC, HNSC, and LSCC as cancer lineages where ANKFY1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ANKFY1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ANKFY1 survival associations across molecular data types. ANKFY1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ANKFY1 RNA expression–survival associations across cancer types. High ANKFY1 expression shows unfavorable associations in LUSC and UVM, but favorable associations in SCLC, HNSC, KIRC and ESCA. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify SCLC as the clearest survival context for ANKFY1 RNA expression.
This table summarizes ANKFY1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 5. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for ANKFY1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ANKFY1 shows lower tumor expression in KICH, BRCA, LUSC and LUAD and higher tumor expression in HNSC and CHOL. The HNSC box plot shows higher ANKFY1 RNA expression in tumor versus normal tissue (log2 FC = +0.624, t-test p < 0.001).
This table shows molecular features associated with ANKFY1 in patient tissues and cancer cell lines. In patient samples, ANKFY1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, ANKFY1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
